Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells.

Sato, Hiromi

Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells. [electronic resource] - European journal of pharmacology Jan 2015 - 258-66 p. digital

Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

1879-0712

10.1016/j.ejphar.2014.11.021 doi


ATP Binding Cassette Transporter, Subfamily B--antagonists & inhibitors
ATP Binding Cassette Transporter, Subfamily G, Member 2
ATP-Binding Cassette Transporters--antagonists & inhibitors
Acridines--pharmacology
Antineoplastic Agents--chemistry
Biological Transport--drug effects
Carcinoma, Renal Cell--drug therapy
Cell Line, Tumor
Cell Survival--drug effects
Drug Resistance, Multiple--drug effects
Drug Resistance, Neoplasm--drug effects
Drug Synergism
Gene Expression Regulation, Neoplastic--drug effects
Humans
Indoles--agonists
Kidney Neoplasms--drug therapy
Kinetics
Membrane Transport Modulators--pharmacology
Neoplasm Proteins--antagonists & inhibitors
Protein Kinase Inhibitors--chemistry
Pyrroles--agonists
RNA, Messenger--metabolism
Sunitinib
Tetrahydroisoquinolines--pharmacology